CS
RYTM icon

Candriam SCA’s Rhythm Pharmaceuticals RYTM Stock Holding History

Candriam SCA’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48M Sell
433,025
-31,315
-7% -$2.83M 0.22% 97
2026
Q1 		$40.4M Buy
464,340
+176,433
+61% +$17.2M 0.21% 104
2025
Q4 		$30.8M Buy
287,907
+66,044
+30% +$7.01M 0.15% 140
2025
Q3 		$22.4M Sell
221,863
-90,589
-29% -$8.41M 0.12% 166
2025
Q2 		$19.7M Buy
312,452
+20,983
+7% +$1.28M 0.11% 168
2025
Q1 		$15.4M Sell
291,469
-40,923
-12% -$2.27M 0.1% 191
2024
Q4 		$18.6M Sell
332,392
-62,985
-16% -$3.48M 0.11% 174
2024
Q3 		$20.7M Buy
395,377
+123,979
+46% +$5.94M 0.12% 176
2024
Q2 		$11.1M Buy
+271,398
New +$10.8M 0.07% 242
2023
Q1 		– Sell
-32,479
Closed -$946K – 921
2022
Q4 		$946K Sell
32,479
-5,755
-15% -$148K 0.01% 702
2022
Q3 		$937K Buy
+38,234
New +$711K 0.01% 723

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Candriam SCA's RYTM Position: Q2 2026 in Review

Candriam SCA reduced its Rhythm Pharmaceuticals (RYTM) stake by 6.7% in Q2 2026, selling an estimated $2.83M and leaving 433,025 shares worth $48M. The position accounts for 0.22% of the portfolio, ranked #97.

Candriam SCA first reported a position in RYTM in Q3 2022 and has held it in 11 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Candriam SCA held 433,025 shares of Rhythm Pharmaceuticals worth $48M as of Q2 2026.
  • Candriam SCA sold 31,315 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.83M.
  • Rhythm Pharmaceuticals made up 0.22% of Candriam SCA's portfolio in Q2 2026, its #97 holding.
  • Candriam SCA first reported a position in Rhythm Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.